Ocular Therapeutix, Inc. (OCUL) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $9.03 (+0.39%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 5, 2026 | Lisa Walter | RBC Capital | $30.00 | +232.4% |
| Oct 3, 2025 | Colleen Kusy | Robert W. Baird | $24.00 | +165.9% |
| Oct 1, 2025 | Jonathan Wolleben | JMP Securities | $29.00 | +221.3% |
| Aug 8, 2024 | Colleen Kusy | Robert W. Baird | $17.00 | +88.4% |
| Jun 27, 2024 | Biren Amin | Piper Sandler | $15.00 | +66.2% |
| Jun 14, 2024 | Yi Chen | H.C. Wainwright | $14.00 | +55.1% |
| Mar 12, 2024 | Jonathan Wolleben | JMP Securities | $24.00 | +165.9% |
| Jun 7, 2022 | Joseph Catanzaro | Piper Sandler | $10.00 | +10.8% |
Top Analysts Covering OCUL
OCUL vs Sector & Market
| Metric | OCUL | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.24 | 2.40 |
| Analyst Count | 6 | 8 | 19 |
| Target Upside | +243.8% | +11474.7% | +17.1% |
| P/E Ratio | -7.81 | 3.92 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $54M | $56M | $58M | 9 |
| 2027-03-31 | $16M | $17M | $18M | 4 |
| 2027-06-30 | $21M | $23M | $24M | 3 |
| 2027-09-30 | $31M | $33M | $36M | 3 |
| 2027-12-31 | $37M | $39M | $42M | 3 |
| 2028-03-31 | $137M | $146M | $156M | 2 |
| 2028-06-30 | $137M | $146M | $156M | 5 |
| 2028-09-30 | $137M | $146M | $156M | 4 |
| 2028-12-31 | $137M | $146M | $156M | 4 |
| 2029-12-31 | $385M | $613M | $1.17B | 5 |
| 2030-12-31 | $644M | $1.02B | $1.96B | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-1.49 | $-1.34 | $-1.12 | 7 |
| 2027-03-31 | $-0.35 | $-0.32 | $-0.30 | 2 |
| 2027-06-30 | $-0.31 | $-0.29 | $-0.27 | 1 |
| 2027-09-30 | $-0.28 | $-0.26 | $-0.23 | 1 |
| 2027-12-31 | $-0.30 | $-0.28 | $-0.25 | 2 |
| 2028-03-31 | $0.05 | $0.05 | $0.05 | 3 |
| 2028-06-30 | $0.05 | $0.05 | $0.05 | 2 |
| 2028-09-30 | $0.04 | $0.04 | $0.04 | 2 |
| 2028-12-31 | $0.03 | $0.03 | $0.03 | 3 |
| 2029-12-31 | $0.02 | $0.04 | $0.10 | 4 |
| 2030-12-31 | $0.77 | $1.48 | $3.24 | 2 |
Frequently Asked Questions
What is the analyst consensus for OCUL?
The consensus among 6 analysts covering Ocular Therapeutix, Inc. (OCUL) is Buy with an average price target of $25.50.
What is the highest price target for OCUL?
The highest price target for OCUL is $30.00, set by Lisa Walter at RBC Capital on 2026-02-05.
What is the lowest price target for OCUL?
The lowest price target for OCUL is $10.00, set by Joseph Catanzaro at Piper Sandler on 2022-06-07.
How many analysts cover OCUL?
6 analysts have issued ratings for Ocular Therapeutix, Inc. in the past 12 months.
Is OCUL a buy or sell right now?
Based on 6 analyst ratings, OCUL has a consensus rating of Buy (2.00/5) with a +243.8% upside to the consensus target of $25.50.
What are the earnings estimates for OCUL?
Analysts estimate OCUL will report EPS of $-1.34 for the period ending 2026-12-31, with revenue estimated at $56M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.